C. Tournigand et al., BIMONTHLY HIGH-DOSE LEUCOVORIN AND 5-FLUOROURACIL 48-HOUR INFUSION WITH INTERFERON-ALPHA-2A IN PATIENTS WITH ADVANCED COLORECTAL-CARCINOMA, Cancer, 79(6), 1997, pp. 1094-1099
BACKGROUND. The rationale for the modulation of 5-fluorouracil (5-FU)
with interferon-alpha (IFN) is inhibition of 5-FU catabolism and 5-FU
resistance. Clinical trials have shown debatable results when IFN is g
iven in high doses with 5-FU used as a bolus alone or in combination w
ith leucovorin (LV), A first-line Phase II study was performed in 50 p
atients with metastatic colorectal carcinoma who were given a bimonthl
y combination of high dose LV, a high dose 48-hour infusion of 5-FU, a
nd a low dose of IFN. METHODS. The regimen was comprised of a 2-hour i
nfusion of LV, 500 mg/m(2), on each of 2 consecutive days, and a 48-ho
ur infusion of 5-FU, 1.5 to 2 g/m(2)/24 hours, starting after Day 1 of
LV treatment every 2 weeks until there was evidence of disease progre
ssion. IFN was administered subcutaneously three times weekly at a dos
e of 3 MU (body surface area [BSA] < 1.75 m(2)) or 4.5 MU (BSA greater
than or equal to 1.75 m(2)). RESULTS, World Health Organization toxic
ity Grade 3-4 occurred in 21 patients (42%): diarrhea in 6%, mucositis
in 12%, neutropenia in 30%, and alopecia in 8%. The overall response
rate was 44%; 1 patient had a complete response (2%), 21 had partial r
esponses (42%), 23 had stable disease (46%), and 5 had disease progres
sion (10%). The median progression free survival was 9 months, and med
ian survival was 25 months. CONCLUSIONS, Bimonthly high dose LV, a hig
h dose 48-hour infusion of 5-FU, and a low dose of IFN had good activi
ty in patients with advanced colorectal carcinoma, However, as in othe
r schedules of LV and 5-FU, IFN induces high grade toxicity. (C) 1997
American Cancer Society.